Lindsay Rosenwald

Lindsay Rosenwald contributions to the biotechnologyindustry are incredible. With the wide range of experience in the clinicaldevelopment, drug research, and finance, he started numerous of companies inthe biotechnology market. As he is known for the investing in the small scalecompanies, he holds the best portfolio which includes venture capital, hedgefund and the capital asset management. Lindsay always believes in the small andmedium scale companies as he feels that the SMB is the future of the anyindustry. This is the reason why Lindsay is more interested in investing onsmall and medium scale companies.

Lindsay Rosenwald studied in Finance from the Pennsylvania State University in 1977 and ofcourse he also received a medical degree from Templeton School of Medicine.With these two degrees, he immediately joined in the apprentice for 2 years. Thefirst venture in his life is his own medical practice, which he has run for twoyears successfully before moving to Wall Street, New York.Once he moves to New Yorkto concentrate on the research and development of biotechnology, he startedParamount Group companies that are directly or indirectly help thebiotechnology industry.

Lindsay Rosenwald is the Founder Of The Rosenwald Foundation,which helps numerous of companies in the advanced research and drugdevelopment. He is also serving as the director for several private limitedcompanies as well as the public limited companies in the biotechnology market. Thereare several companies, which take the Lindsay advice in the critical situationsas he is known for the best strategist in the biotechnology market. Thecompanies like Paramount BioCapital, Paramount Capital Management are wellknown in the market for the fund raising and investing in other small companies.

Lindsay Rosenwald is known as one of the most prolific leaders in thebiotechnology with the wide range of experience in starting companies andhelping several professionals in the market. Cougar Biotechnology founded bythe Rosenwald has been sold out recently to Johnson and Johnson for thehumongous price of approximately one billon dollars. Dr. Rosenwald is known forgetting the quick approvals from FDA to market the drugs. The rare drug forleukemia has got the approval to market from FDA for just 30 months of clinicaltrails and it is the best industry record till now.